Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Everything to know about NASA's moon mission launching this week - 2Bayer sues COVID vaccine makers over mRNA technology
- 3Instructions to Pick the Right Toothpaste for Your Dental Requirements
- 4Hunger and makeshift shelters persist in north Caribbean nearly 2 months after Hurricane Melissa
- 5Europe must reinvent warfare for ‘era of shocks,’ NATO’s Vandier says
- The architect of Iran’s military survival remains defiant
- How one man's concern saved his brothers from heart disease
- Canada cancels its 1st moon rover: 'It's hopefully not a lost cause'
- Alix Earle built trust by sharing her acne woes. Now her skin care line is raising questions.
- At least 36 dead in major fire in Hong Kong residential blocks
- Sea Ice Hits New Low in Hottest Year on Record for the Arctic
- Electric Vehicles for Eco-Accommodating Driving
- Most loved Seared Chicken: Which Chain Rules?
- The 3 little words TV fans can't stop obsessing over
